Your Health, We Care
Release date: 2026-04-17 15:30:25 Recommended: 12
Selinexor works in a completely different way from other multiple myeloma treatments. It works by blocking a protein called XPO1. In healthy plasma cells, the XPO1 protein helps transport substances out of the cell nucleus, but some of these substances actually help slow down cell division and growth. In multiple myeloma cells, however, XPO1 is overproduced, leading to massive cancer cell proliferation. Selinexor is the only FDA-approved drug that blocks XPO1, thereby helping restore the body's own tumor defense system. This innovative mechanism makes Selinexor an effective treatment option for patients after relapse — when traditional paths are no longer viable, choosing a unique route may bring a turning point.
After multiple myeloma relapses, patients often face confusion about treatment options. Conventional treatment regimens may gradually lose effectiveness, and at that point, a different approach is needed. Selinexor is an oral medication taken just once a week that fights myeloma cells in a unique way. Clinical studies show that using a drug with a completely different mechanism of action can often break through drug resistance and bring new hope to patients. In a pivotal clinical trial, patients receiving a Selinexor-containing regimen achieved longer progression-free survival: at a median follow-up of 15.1 months, the treatment group had a median time without disease progression of 13.9 months, compared to only 9.5 months in the control group. This means Selinexor helped patients gain an additional 4.4 months of valuable time without disease worsening.
Selinexor is indicated for two main situations. First, in combination with bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Second, in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. Selinexor received accelerated approval based on overall response rate, and continued studies are underway to confirm its long-term clinical benefit. It is important to note that the safety and effectiveness of Selinexor in children have not been established.
